Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,961 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04740398 | A Study of CBP-1008 in Patients With Advanced Solid Tumor | unknown | Phase 1 | 143 | Coherent Biopharma (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 28, 2024 | clinicaltrials |
| NCT04928612 | A Study of CBP-1018 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 170 | Coherent Biopharma (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05272293 |
| Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML |
| unknown |
| Phase 1 / Phase 2 |
| 15 |
| Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER |
| 1 |
| Aug 28, 2024 |
| clinicaltrials |
| NCT05333302 | Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma | unknown | Phase 1 | 10 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05334693 | Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML | unknown | Phase 1 / Phase 2 | 15 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05914662 | Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM(ZBR) | unknown | Phase 2 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06468800 | Feasibility and Added Value of the TRACMOTION Device for ESD(TRACMOTION) | unknown | N/A | 20 | Erasmus Medical CenterOTHER | 0 | Aug 28, 2024 | clinicaltrials |
| NCT06564298 | A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis | unknown | Phase 2 | 39 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 28, 2024 | clinicaltrials |
| NCT06574763 | Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer | unknown | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 0 | Aug 28, 2024 | clinicaltrials |
| NCT06575127 | Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study | unknown | Phase 2 | 60 | Al-Azhar UniversityOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06576180 | Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma | unknown | — | 306 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT03757182 | Digitally-Captured Step Counts for Evaluating Performance Status in Advanced Cancer Patients(DigiSTEPS) | unknown | — | 80 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT04097067 | ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | unknown | N/A | 83 | University Hospital MuensterOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT04575402 | Digitally Captured Activity Data and PROs to Monitor Physical Function in Prostate Cancer Patients(DigiPRO) | unknown | — | 40 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT05381792 | Serial Gut Microbiome and Bacterial Gene Markers Changes After Endoscopic Resection of Colorectal Advanced Neoplasia(M3-CAN) | unknown | — | 50 | Chinese University of Hong KongOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT05391217 | Feasibility of Remote Activity Assessment and PRO Collection Among Transgender Cancer Survivors(STRIDE) | unknown | — | 20 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT05447988 | Motiva Flora Tissue Expander PMCF | unknown | N/A | 136 | Establishment LabsINDUSTRY | 4 | Aug 27, 2024 | clinicaltrials |
| NCT05475184 | A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor | unknown | Phase 2 | 58 | Onconic Therapeutics Inc.INDUSTRY | 1 | Aug 27, 2024 | clinicaltrials |
| NCT05720832 | Feasibility of Technology-Based SSIP in Prostate Cancer Patients | unknown | N/A | 27 | Wings Health AGINDUSTRY | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06347354 | Permanence of Indocyanine Green in Axillary Lymph Nodes 3 Weeks After Subdermal Injection in Patients With Breast Cancer and Metastatic Lymph Nodes(FLUO) | unknown | N/A | 10 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06572410 | Prospective Analysis of EnVisio Spatial Intelligence for Soft Tissue Localization and Guided Surgical Excision | unknown | — | 200 | Elucent MedicalINDUSTRY | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06573736 | Stockholm3 Use Prior to MRI for Prostate Cancer Detection in a Clinical Care Pathway: a Multi-centered Validation(S3M-MRI) | unknown | — | 500 | Karolinska InstitutetOTHER | 0 | Aug 27, 2024 | clinicaltrials |
| NCT06573788 | Multidisciplinary Prehabilitation Management Pathway and Network Platform Construction | unknown | N/A | 64 | Peking Union Medical College HospitalOTHER | 0 | Aug 27, 2024 | clinicaltrials |
| NCT06574308 | Clinical Evaluation of the Scopio Cell Morphology Technology(Hemascopio) | unknown | — | 300 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT03375437 | RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.(RNASARC) | unknown | N/A | 376 | Centre Leon BerardOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT05176665 | EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | unknown | Phase 1 / Phase 2 | 152 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT05830097 | A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 260 | Coherent Biopharma (Hefei) Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT06393140 | The Study on the Mechanism of Radiotherapy-elicited Immune Response | unknown | — | 200 | Fudan UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06471673 | A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer | unknown | Phase 1 / Phase 2 | 18 | BriaCell Therapeutics CorporationINDUSTRY | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06486545 | Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer | unknown | N/A | 18 | Hunan Cancer HospitalOTHER | 0 | Aug 26, 2024 | clinicaltrials |
| NCT06569459 | Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer | unknown | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06570486 | Contrast Between Traditional Regression Model and AI in Predicting Prolonged Stay Stay After Head and Neck Tumors | unknown | — | 700 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06571396 | Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma | unknown | — | 200 | Qilu Hospital of Shandong UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT05007938 | Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer | unknown | Phase 2 | 30 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT05336318 | Peer2Me: A Peer Supported Program for Adolescent and Young Adult Cancer Patients(Peer2Me) | unknown | N/A | 180 | University of LeipzigOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT05341583 | Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer | unknown | Phase 3 | 202 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06496711 | IMPLEMENT - Model Project for Quality-assured Exercise Therapy for Cancer Patients | unknown | N/A | 600 | University of CologneOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06565585 | Prediction of Local Recurrence and Its Impact on Long-term Outcomes After Low-risk Glans-sparing Surgery for Penile Squamous Cell Carcinoma | unknown | — | 800 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT00877214 | Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas(MAINTAIN) | unknown | Phase 3 | 1,272 | Jurgen BarthOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT02949219 | Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | unknown | Phase 2 | 41 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT04185831 | A MolEcularly Guided Anti-Cancer Drug Off-Label Trial(MEGALiT) | unknown | Phase 2 | 167 | Uppsala University HospitalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05887102 | Pilot Study of PACHA Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors(PACHA) | unknown | N/A | 66 | CHU de Quebec-Universite LavalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06404281 | γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors | unknown | Phase 1 | 9 | Changzhou No.2 People's HospitalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06425146 | Tobacco, Alcohol and Cancerization of the Oral Mucosa (TACO)(TACO) | unknown | N/A | 30 | Centre Leon BerardOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06463756 | AI Models to Predict Thyroid Cartilage Invasion in Laryngeal Carcinoma | unknown | — | 400 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06565598 | Single-layer Robot-assisted Transperitoneal Retroperitoneal Tubeless Radical Nephrectomy | unknown | N/A | 150 | The First People's Hospital of XiushuiOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06565923 | Study on the Staging and Prognosis Model of Bladder Cancer(2024-SR-386) | unknown | — | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06566391 | Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma | unknown | Phase 2 | 35 | European Institute of OncologyOTHER | 1 | Aug 22, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Aug 28, 2024source: clinicaltrials